Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07212088) titled 'Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's Disease' on Sept. 30.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: iCamuno Biotherapeutics Ltd.
Condition:
Parkinson Disease
Intervention:
Biological: ALC01 therapy
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: November 15, 2025
Target Sample Size: 12
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07212088
P...